EMA Authorised: Relvar Ellipta (fluticasone furoate;vilanterol) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA authorised Relvar Ellipta (fluticasone furoate and vilanterol) for chronic obstructive pulmonary disease; the product is manufactured by GlaxoSmithKline…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Relvar Ellipta (fluticasone furoate; vilanterol)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 12/03/2025